Alzheimer’s disease is associated with sleep disturbances and accumulation of cerebral amyloid beta. The objective was to examine whether actigraphy-detected sleep parameters might be biomarkers for early amyloid burden.

Participants underwent a week of actigraphy and an amyloid positron emission tomography (PET) scan. Sleep duration and continuity disruption (sleep fragmentation and nocturnal awakenings) were extracted and compared between amyloid-positive and amyloid-negative participants. Then multiple linear regressions were used between mean or night-to-night intra-individual variability (standard deviation) of sleep parameters and brain amyloid burden in a voxel-wise analysis.

Eighty-six subjects were included (80.3 ± 5.4 years; 48.8% of women). Amyloid-positive participants had a higher variability of sleep fragmentation compared to amyloid-negative participants. This parameter was associated with a higher amyloid burden in the frontal and parietal regions, and in the precuneus, in the whole sample.

This study highlights the relevance of using variability in sleep continuity as a potential biomarker of early amyloid pathogenesis.

Direct Link:

Journal: Alzheimer's & Dementia: Diagnosis Assessment & Disease Monitoring. 2023 Jul;15(3):e12460

Keywords: Aging, Alzheimer’s disease, Amyloid, older adults, Sleep,

Applications: Sleep,

CamNtech Reference: M23053

Back to Search Results

UK & International customers

CamNtech Ltd.
Manor Farm
PE28 9JD, UK

US customers

CamNtech Inc.
630 Boerne Stage Airfield,
Texas 78006,


© 2024 CamNtech Ltd and CamNtech Inc

Company information

Registered in England No. 2221302
VAT No: GB486 3019 34

Privacy Policy